Analysts expect Hemab Therapeutics to report a Q3 2026 loss per share of $0.51 on negligible revenue, with the current stock price trading at $18.42 against a consensus price target of $24.50. Investors are primarily focused on clinical data readouts for HMB-001, the company's lead candidate for Glanzmann Thrombasthenia.
The market is looking for updates on the Phase 1/2 clinical trial progress and any shift in the anticipated timeline for regulatory filings. Recent performance has been driven by optimism surrounding Hemab's specialized pipeline for rare bleeding disorders and its cash runway following the late 2025 financing round.